Expression of Interest: Co-Director, Medical Research Institute of New Zealand
The Medical Research Institute of New Zealand (MRINZ) invites expressions of interest from senior academic clinician researchers for a Co-Director role.
The appointment of a Co-Director is part of planned governance for leadership continuity at the MRINZ. Professor Richard Beasley, MRINZ’s founding Director, is considering retirement in the medium to longer term. Professor Beasley will continue in his current role until a suitable candidate is appointed to a Co-Director position.
Founded in 2001 and based at Wellington Regional Hospital, MRINZ is New Zealand’s leading independent medical research institute, recognised for the quality and clinical impact of its work. The Institute runs multiple integrated research programmes, including Anaesthesia, Asthma, Cardiothoracic Surgery, Children’s Health, Complementary and Alternative Medicine, Infectious Disease, Intensive Care, Māori and Pacific Health, Oxygen Therapy, and Stroke and Rehabilitation.
MRINZ is an NZQA-accredited Private Training Establishment with the authority to award MD degrees, and collaborates with Victoria University of Wellington on Master’s and PhD programmes. MRINZ also participates in the EU HORIZON pandemic preparedness programme and holds provisional ECRIN accreditation.
We seek an internationally recognised academic clinician researcher with a strong record of high-impact publications, grant funding, leadership experience, and management skills.
Applications are encouraged from researchers in the fields of intensive care, infectious disease, and respiratory medicine, though candidates with experience in other MRINZ research areas or medical specialties will be considered.
The Co-Director position may range from 0.4–1.0 FTE, with opportunities for a clinical appointment at Te Whatu Ora Capital Coast and Hutt Valley or in private practice.
To apply: Please send a CV and expression of interest to Professor Richard Beasley at [email protected] or via SEEK.
Deadline: 31 March 2026
